-
Product Insights
NewNet Present Value Model: F. Hoffmann-La Roche Ltd’s EBI-031
Empower your strategies with our Net Present Value Model: F. Hoffmann-La Roche Ltd's EBI-031 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EBI-031 in Uveitis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.EBI-031 in Uveitis Drug Details:RG-6179 (EBI-031) is under development for the treatment of diabetic macular edema...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EBI-031 in Diabetic Macular Edema
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.EBI-031 in Diabetic Macular Edema Drug Details:RG-6179 (EBI-031) is under development for the treatment of diabetic...
-
Product Insights
NewNet Present Value Model: Compass Pathways Plc’s Psilocybin
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Capivasertib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Capivasertib in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Capivasertib in Solid Tumor Drug Details: Capivasertib (Truqap) belongs to alpha...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Isunakinra in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Isunakinra in Prostate Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Isunakinra in Prostate Cancer Drug Details: Isunakinra (EBI-005) was under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Isunakinra in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Isunakinra in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Isunakinra in Colorectal Cancer Drug Details: Isunakinra (EBI-005) was under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Isunakinra in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Isunakinra in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Isunakinra in Pancreatic Cancer Drug Details: Isunakinra (EBI-005) was under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Isunakinra in Anal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Isunakinra in Anal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Isunakinra in Anal Cancer Drug Details: Isunakinra (EBI-005) was under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Isunakinra in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Isunakinra in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Isunakinra in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: Isunakinra...